View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by Strategikon Pharma

Building the Industry’s Most Advanced Modelling Engine

Free White Paper

Building the Industry’s Most Advanced Modelling Engine

By Strategikon Pharma

Building the Industry’s Most Advanced Modelling Engine

By Strategikon Pharma
Enter your details to receive the free paper:

For the past ten years, the industry has seen an increased demand to determine fair market value of CRO and other clinical trial service providers.

Not only do these costs account for the largest portion of the direct clinical trial cost at the onset of the trial, but the change orders associated with these cost categories are the main culprits for significant cost swings during the trial execution.

While total negotiated cost is of importance during planning and budgeting exercises or CRO negotiation, the estimation of actual activity- completed costs and accurate time distribution of cost throughout the lifecycle of the trial (reforecasting), are equally critical for financial planning and reporting and for overall study risk management.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena